UBS Maintains Buy on Evolent Health, Lowers Price Target to $5
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Kevin Caliendo maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $10 to $5.
UBS analyst Kevin Caliendo maintains Evolent Health (NYSE:EVH) with a Buy and lowers the price target from $10 to $5.